AI Article Synopsis
- Visceral leishmaniasis (VL) is a serious and often fatal disease if not treated, and this study focuses on improving its treatment.
- Researchers developed doxorubicin-loaded mannan conjugated microparticles aimed at delivering the drug directly to macrophages in the liver and spleen, which are key in fighting VL.
- By targeting macrophages with these encapsulated doxorubicin particles, the goal is to enhance treatment effectiveness while minimizing side effects.
Article Abstract
Visceral leishmaniasis (VL) is the most severe of all the forms of leishmaniasis and usually lethal if untreated. The present work aimed to develop and characterize doxorubicin loaded mannan conjugated microparticles against experimental visceral leishmaniasis for selective and targeted delivery of doxorubicin to the macrophages of liver and spleen for the effective chemotherapy of VL. Macrophage targeting using doxorubicin loaded PLGA-microparticles would certainly improve the chemotherapy with reduced side effects against VL.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1166/jbn.2011.1237 | DOI Listing |
Publication Analysis
Top Keywords
doxorubicin loaded
12
visceral leishmaniasis
12
microparticles experimental
8
experimental visceral
8
development characterization
4
doxorubicin
4
characterization doxorubicin
4
loaded microparticles
4
leishmaniasis
4
leishmaniasis visceral
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!